These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 11149939)

  • 21. Molecular pathways that modify tumor radiation response.
    Pervan M; Pajonk F; Sun JR; Withers HR; McBride WH
    Am J Clin Oncol; 2001 Oct; 24(5):481-5. PubMed ID: 11586100
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Re-evaluating the generation of a "proteasome-independent" MHC class I-restricted CD8 T cell epitope.
    Wherry EJ; Golovina TN; Morrison SE; Sinnathamby G; McElhaugh MJ; Shockey DC; Eisenlohr LC
    J Immunol; 2006 Feb; 176(4):2249-61. PubMed ID: 16455981
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proteolysis and class I major histocompatibility complex antigen presentation.
    York IA; Goldberg AL; Mo XY; Rock KL
    Immunol Rev; 1999 Dec; 172():49-66. PubMed ID: 10631936
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A proteolytic system that compensates for loss of proteasome function.
    Glas R; Bogyo M; McMaster JS; Gaczynska M; Ploegh HL
    Nature; 1998 Apr; 392(6676):618-22. PubMed ID: 9560160
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis.
    Ling YH; Liebes L; Ng B; Buckley M; Elliott PJ; Adams J; Jiang JD; Muggia FM; Perez-Soler R
    Mol Cancer Ther; 2002 Aug; 1(10):841-9. PubMed ID: 12492117
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Kinetic studies of the branched chain amino acid preferring peptidase activity of the 20S proteasome: development of a continuous assay and inhibition by tripeptide aldehydes and clasto-lactacystin beta-lactone.
    McCormack TA; Cruikshank AA; Grenier L; Melandri FD; Nunes SL; Plamondon L; Stein RL; Dick LR
    Biochemistry; 1998 May; 37(21):7792-800. PubMed ID: 9601040
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proteases, proteases and proteases for presentation.
    Herberts C; Reits E; Neefjes J
    Nat Immunol; 2003 Apr; 4(4):306-8. PubMed ID: 12660727
    [No Abstract]   [Full Text] [Related]  

  • 28. Promoting proteasomes: trash to treasure.
    Sussman HE
    Drug Discov Today; 2003 Oct; 8(19):866-8. PubMed ID: 14554007
    [No Abstract]   [Full Text] [Related]  

  • 29. Role of tripeptidyl peptidase II in the processing of Listeria monocytogenes-derived MHC class I-presented antigenic peptides.
    Grauling-Halama S; Bahr U; Schenk S; Geginat G
    Microbes Infect; 2009; 11(8-9):795-802. PubMed ID: 19426827
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human somatic cell knockouts reveal determinants of sensitivity and resistance to proteasome inhibitor PS-341.
    Lee C; Waldman T
    Cancer Biol Ther; 2003; 2(6):700-1. PubMed ID: 14688480
    [No Abstract]   [Full Text] [Related]  

  • 31. Tripeptidyl peptidases: enzymes that count.
    Tomkinson B
    Trends Biochem Sci; 1999 Sep; 24(9):355-9. PubMed ID: 10470035
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of ubiquitin-proteasome pathway activates a caspase-3-like protease and induces Bcl-2 cleavage in human M-07e leukaemic cells.
    Zhang XM; Lin H; Chen C; Chen BD
    Biochem J; 1999 May; 340 ( Pt 1)(Pt 1):127-33. PubMed ID: 10229667
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of serine-peptidase activity enhances the generation of a survivin-derived HLA-A2-presented CTL epitope in colon-carcinoma cells.
    Preta G; Marescotti D; Fortini C; Carcoforo P; Castelli C; Masucci M; Gavioli R
    Scand J Immunol; 2008 Dec; 68(6):579-88. PubMed ID: 19000094
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Generating MHC class I ligands from viral gene products.
    Yewdell J; Antón LC; Bacik I; Schubert U; Snyder HL; Bennink JR
    Immunol Rev; 1999 Dec; 172():97-108. PubMed ID: 10631940
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells.
    Fuchs D; Berges C; Opelz G; Daniel V; Naujokat C
    J Cell Biochem; 2008 Jan; 103(1):270-83. PubMed ID: 17516511
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Covalent modification of the active site threonine of proteasomal beta subunits and the Escherichia coli homolog HslV by a new class of inhibitors.
    Bogyo M; McMaster JS; Gaczynska M; Tortorella D; Goldberg AL; Ploegh H
    Proc Natl Acad Sci U S A; 1997 Jun; 94(13):6629-34. PubMed ID: 9192616
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Changes in spatio-temporal localization of tripeptidyl peptidase II (TPPII) in murine colon adenocarcinoma cells during aggresome formation: a microscopy study based on a novel fluorescent proteasome inhibitor.
    Bialy LP; Kuckelkorn U; Henklein P; Fayet J; Wilczyński GM; Kamiński A; Mlynarczuk-Bialy I
    Histol Histopathol; 2019 Apr; 34(4):359-372. PubMed ID: 30226264
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical update: proteasome inhibitors in solid tumors.
    Lenz HJ
    Cancer Treat Rev; 2003 May; 29 Suppl 1():41-8. PubMed ID: 12738242
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Giant proteases: beyond the proteasome.
    Yao T; Cohen RE
    Curr Biol; 1999 Jul 29-Aug 12; 9(15):R551-3. PubMed ID: 10469553
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia.
    Pahler JC; Ruiz S; Niemer I; Calvert LR; Andreeff M; Keating M; Faderl S; McConkey DJ
    Clin Cancer Res; 2003 Oct; 9(12):4570-7. PubMed ID: 14555532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.